Novogene (688315) Fundamentals 2026 — P/E 31.0x, Revenue Analysis | SniperIQ
Novogene (688315) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥5.2B, trading at ¥12.39 on the SHH. This SniperIQ fundamentals page covers Novogene's valuation (P/E 31.0x, P/B 1.9x), profitability (net margin 7.0%), revenue (¥2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Novogene's market cap?
Novogene (688315) has a market capitalization of approximately ¥5.2B, trading at ¥12.39 on the SHH. Market cap moves with the live share price.
What is Novogene's P/E ratio?
Novogene's trailing twelve-month P/E ratio is 31.0x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Novogene?
Novogene runs a net profit margin of 7.0%, a gross margin of 43.0%, and an operating margin of 8.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Novogene generate?
Novogene reported revenue of ¥2.2B for fiscal year 2025, with net income of ¥166M and earnings per share (EPS) of 0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Novogene pay a dividend?
Novogene offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Novogene financially healthy?
Novogene carries a debt-to-equity ratio of 0.03x and a current ratio of 2.62x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Novogene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Novogene (688315) the key facts are: market cap ¥5.2B, P/E 31.0x, revenue ¥2.2B, 52-week range 11.46-18.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Novogene's full fundamentals live
Get Novogene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.